My Treatment Approach: Adjuvant CDK4/6 Inhibition in HR-Positive, HER2-Negative Early Breast Cancer

Erica Mayer, MD, and Kelly McCann, MD, outline how clinicians define high-risk hormone receptor–positive, HER2-negative early breast cancer in contemporary practice.

Long-term follow-up from the monarchE and NATALEE trials continues to influence treatment decisions in HR-positive, HER2-negative early breast cancer.